| Dr John Edwin Mccollum, MD | |
|
1601 E Whiskey Run Rd Ne, New Salisbury, IN 47161-9345 | |
| (812) 738-4251 | |
| Not Available |
| Full Name | Dr John Edwin Mccollum |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 42 Years |
| Location | 1601 E Whiskey Run Rd Ne, New Salisbury, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750389318 | NPI | - | NPPES |
| 000000042492 | Other | BLUE SHEILD | |
| 100128370A | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | 01032427 (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Harrison County Hospital | Corydon, IN | Hospital |
| Baptist Health Floyd | New albany, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Harrison County Hospital | 9032007208 | 36 |
News Archive
Gilead Sciences, Inc. announced today that the European Commission has granted conditional marketing authorization for Cayston® 75 mg powder and solvent for nebuliser solution (aztreonam lysine) for the suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa (P. aeruginosa) in patients with cystic fibrosis (CF) aged 18 years and older.
A major study of women with ductal carcinoma in situ (DCIS) - a breast condition that can become invasive cancer - has shown that surgery to remove the tissue followed by radiotherapy offers better protection compared to surgery alone.
Motorcycle Charity Associates announced today that they will welcome a lucky group of wounded veterans to Los Angeles for free vision treatment and a "Hero's Night Out" at the 2nd Annual Stars & Stripes event taking place on the grounds of the Playboy Mansion on Saturday, May 15th.
Medopad today announced a strategic collaboration with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to validate, scale and potentially commercialize the ReVeRe platform as a novel digital biomarker for Alzheimer's disease. This deal was facilitated by Johnson & Johnson Innovation Limited.
Researchers from The University of Manchester working with drug development company Evgen Pharma, have developed a new combination of drugs which could overcome treatment resistance and relapse in breast cancer.
› Verified 7 days ago
| Entity Name | Harrison County Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790892727 PECOS PAC ID: 9032007208 Enrollment ID: O20040406000076 |
News Archive
Gilead Sciences, Inc. announced today that the European Commission has granted conditional marketing authorization for Cayston® 75 mg powder and solvent for nebuliser solution (aztreonam lysine) for the suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa (P. aeruginosa) in patients with cystic fibrosis (CF) aged 18 years and older.
A major study of women with ductal carcinoma in situ (DCIS) - a breast condition that can become invasive cancer - has shown that surgery to remove the tissue followed by radiotherapy offers better protection compared to surgery alone.
Motorcycle Charity Associates announced today that they will welcome a lucky group of wounded veterans to Los Angeles for free vision treatment and a "Hero's Night Out" at the 2nd Annual Stars & Stripes event taking place on the grounds of the Playboy Mansion on Saturday, May 15th.
Medopad today announced a strategic collaboration with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to validate, scale and potentially commercialize the ReVeRe platform as a novel digital biomarker for Alzheimer's disease. This deal was facilitated by Johnson & Johnson Innovation Limited.
Researchers from The University of Manchester working with drug development company Evgen Pharma, have developed a new combination of drugs which could overcome treatment resistance and relapse in breast cancer.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr John Edwin Mccollum, MD Po Box 38, Corydon, IN 47112-0038 Ph: (812) 738-4251 | Dr John Edwin Mccollum, MD 1601 E Whiskey Run Rd Ne, New Salisbury, IN 47161-9345 Ph: (812) 738-4251 |
News Archive
Gilead Sciences, Inc. announced today that the European Commission has granted conditional marketing authorization for Cayston® 75 mg powder and solvent for nebuliser solution (aztreonam lysine) for the suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa (P. aeruginosa) in patients with cystic fibrosis (CF) aged 18 years and older.
A major study of women with ductal carcinoma in situ (DCIS) - a breast condition that can become invasive cancer - has shown that surgery to remove the tissue followed by radiotherapy offers better protection compared to surgery alone.
Motorcycle Charity Associates announced today that they will welcome a lucky group of wounded veterans to Los Angeles for free vision treatment and a "Hero's Night Out" at the 2nd Annual Stars & Stripes event taking place on the grounds of the Playboy Mansion on Saturday, May 15th.
Medopad today announced a strategic collaboration with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to validate, scale and potentially commercialize the ReVeRe platform as a novel digital biomarker for Alzheimer's disease. This deal was facilitated by Johnson & Johnson Innovation Limited.
Researchers from The University of Manchester working with drug development company Evgen Pharma, have developed a new combination of drugs which could overcome treatment resistance and relapse in breast cancer.
› Verified 7 days ago